Detalle de acción
CNTB
Connect Biopharma Holdings Limited
-
-
-
-
| Capitalización | - |
|---|---|
| Volumen | - |
| Rango del día | - |
| Ingresos (TTM) | - |
| Ingreso neto | - |
| EPS | - |
| Acciones en circulación | - |
| PE | - |
| PE forward | - |
| Dividendo | - |
| Fecha ex-dividendo | - |
| Open | - |
| Close anterior | - |
| Rango 52 semanas | - |
| Beta | - |
| Analistas | - |
| Precio objetivo | - |
| Fecha de resultados | - |
Cargando...
Acerca de
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States.
It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
The company was founded in 2012 and is headquartered in San Diego, California.
Industria
Biotecnología
Sector
Salud
Fecha de IPO
Mar 19, 2021
Empleados
64
Bolsa
NASDAQ
Sitio web
connectbiopharm.com
PUBLICIDAD